Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Acalabrutinib Plus RICE in Relapsed/Refractory DLBCL
NCT03736616Phase 2Unknown
- Sponsor
- Swedish Health Services
- Start
- Aug 2019
- Primary completion
- Sep 2023
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of acalabrutinib in diffuse large B-cell lymphoma (DLBCL), sponsored by Swedish Health Services. Status: unknown.
02
Drugs
acalabrutinib
03
Conditions
diffuse large B-cell lymphoma (DLBCL)
Beyond the preview
Go deeper on NCT03736616.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03736616.